Skip to main content

Advertisement

Table 3 First-line drug resistance by study site and treatment history

From: The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance

Study site Treatment history First-line drug resistance Total DST profiles of resistant isolates
Pan susceptible Any resistance RMP mono INH mono SM mono EMB mono PDR MDR
N % n % N % n % n % n % N % n %
Burkina Faso All   18 (67) 9 (33) 27 0 (0) 2 (7) 1 (4) 0 (0) 4 (15) 2 (7)
New 13 (65) 7 (35) 20 0 (0) 2 (10) 1 (5) 0 (0) 3 (15) 1 (5)
Retreatment 0 (0) 1 (100) 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
Unknown 5 (83) 1 (17) 6 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0)
The Gambia All   80 (77) 24 (23) 104 1 (1) 4 (4) 6 (6) 0 (0) 1 (1) 12 (11)
New 7 (78) 2 (22) 9 0 (0) 1 (11) 1 (11) 0 (0) 0 (0) 0 (0)
Retreatment 73 (77) 22 (23) 95 1 (1) 3 (3) 5 (5) 0 (0) 1 (1) 12 (13)
Ghana All   64 (50) 63 (50) 127 1 (0) 7 (5) 13 (10) 0 (0) 9 (7) 33 (26)
New 11 (73) 4 (27) 15 0 (0) 1 (7) 1 (7) 0 (0) 0 (0) 2 (13)
Retreatment 53 (47) 59 (53) 112 1 (1) 6 (5) 12 (11) 0 (0) 9 (8) 31 (28)
Guinea-Bissau All   34 (77) 10 (23) 44 2 (4) 1 (2) 1 (2) 1 (2) 2 (5) 3 (7)
New 24 (75) 8 (25) 32 2 (6) 1 (3) 1 (3) 1 (3) 2 (6) 1 (3)
Retreatment 2 (50) 2 (50) 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (50)
Unknown 8 (100) 0 (0) 8 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mali All   143 (69) 65 (31) 208 1 (0) 7 (3) 7 (3) 0 (0) 11 (5) 39 (19)
New 127 (85) 23 (15) 150 1 (1) 7 (5) 6 (4) 0 (0) 4 (3) 5 (3)
Retreatment 16 (28) 42 (72) 58 0 (0) 0 (0) 1 (2) 0 (0) 7 (12) 34 (59)
Nigeria/Ibadan All   31 (54) 26 (46) 57 1 (2) 1 (2) 4 (7) 0 (0) 3 (5) 17 (30)
New 11 (85) 2 (15) 13 0 (0) 1 (8) 1 (8) 0 (0) 0 (0) 0 (0)
Retreatment 20 (45) 24 (55) 44 1 (2) 0 (0) 3 (7) 0 (0) 3 (7) 17 (39)
Nigeria/Lagos All   27 (22) 93 (78) 120 0 (0) 6 (5) 11 (9) 0 (0) 5 (4) 71 (59)
New 11 (40) 17 (61) 28 0 (0) 1 (4) 5 (18) 0 (0) 2 (7) 9 (32)
Retreatment 16 (18) 72 (82) 88 0 (0) 5 (6) 6 (7) 0 (0) 3 (3) 58 (66)
Unknown 0 (0) 4 (100) 4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (100)
Senegal All   60 (80) 15 (20) 75 0 (0) 3 (4) 1 (1) 0 (0) 3 (4) 8 (11)
New 49 (90) 6 (11) 55 0 (0) 1 (2) 1 (2) 0 (0) 1 (2) 3 (5)
Retreatment 11 (55) 9 (45) 20 0 (0) 2 (10) 0 (0) 0 (0) 2 (10) 5 (25)
Togo All   142 (67) 70 (33) 212 4 (2) 14 (7) 16 (7) 1 (0) 5 (2) 30 (14)
New 79 (84) 15 (16) 94 1 (1) 1 (1) 7 (7) 0 (0) 1 (1) 5 (5)
Retreatment 62 (55) 50 (45) 112 3 (3) 13 (12) 8 (7) 1 (1) 3 (3) 22 (20)
Unknown 1 (17) 5 (83) 6 0 (0) 0 (0) 1 (17) 0 (0) 1 (17) 3 (50)
All study sites All   599 (61) 375 (39) 974 10 (1) 45 (5) 60 (6) 2 (0) 43 (4) 215 (22)
New 332 (80) 84 (20) 416 4 (1) 16 (4) 24 (6) 1 (0) 13 (3) 26 (6)
Retreatment 253 (47) 281 (53) 534 6 (1) 29 (5) 35 (7) 1 (0) 28 (5) 182 (34)
Unknown 14 (58) 10 (42) 24 0 (0) 0 (0) 1 (4) 0 (0) 2 (8) 7 (29)
  1. The overall proportion of resistance to any drug is displayed as well as a detailed description of resistant isolates and their resistant patterns, stratified by mono-resistance to rifampicin (RMP), isoniazid (INH), streptomycin (SM), ethambutol (EMB), poly-drug-resistance (PDR, resistance to a combination of any two first-line drugs except for MDR) and multi-drug-resistance (MDR, resistance to at least both RMP and INH)